

Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008

- Presentation to Be Webcast Live On Company's Website -

TUSTIN, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and serious virus infections, today announced that senior management will present at the BIO Investor Forum 2008 on Thursday, October 30, 2008 at 3:45 pm PDT (6:45 pm EDT). The conference will be held at the Palace Hotel in San Francisco.

A live webcast and archived replay of the company's presentation will be available at the Investor Relations section of Peregrine's website at www.peregrineinc.com.

For more information about this conference, please visit: http://investorforum.bio.org/opencms/bif/2008/

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Contacts:
GendeLLindheim BioCom Partners
Investors
<u>info@peregrineinc.com</u>
(800) 987-8256

Media Barbara Lindheim (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.

http://www.peregrineinc.com/

Copyright (C) 2008 PR Newswire. All rights reserved

News Provided by COMTEX